In the News

Position statement: Self-management education and support crucial and underused

Diabetes self-management education and support (DSME/S) is proven to be effective, but the numbers of patients who are referred to and receive it are “disappointingly small,” according to a recent statement by 3 health organizations.

Early insulin initiation may benefit older adults with type 2 diabetes and inadequate glycemic control

Older patients with type 2 diabetes and inadequate glycemic control may benefit from earlier initiation of insulin therapy, according to a recent study.

HbA1c results may be affected by anemia

Anemia affects the reliability of HbA1c results, concluded a new systematic review that offered 4 tips for incorporating this knowledge into clinical practice.

MKSAP quiz: Type 1 diabetes, ketoacidosis, and fungal infection

This month's quiz asks readers to evaluate a 40-year-old man admitted to the emergency department with a 1-day history of headache and epistaxis.

Metformin rarely prescribed for prediabetes, study finds

Very few patients with prediabetes are prescribed metformin, according to a recent study of working-age adults.

Task Force releases systematic review about diabetes screening

A systematic evidence review by the U.S. Preventive Services Task Force suggests that screening asymptomatic adults for elevated glucose levels could help delay progression to diabetes but has not been shown to improve mortality rates.

ACE inhibitors, ARBs most effective against ESRD in patients with diabetes, kidney disease

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) appear most effective in preventing end-stage renal disease (ESRD) in patients with diabetes and kidney disease, although no regimen to lower blood pressure seems to prolong survival, a recent analysis has found.

SGLT2 inhibitors associated with ketoacidosis

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, may cause ketoacidosis, the FDA recently warned.

Spotlight on intensive glycemic control

Three recent studies reanalyzed past data about the effects of intensive glycemic control and published new findings about how and which patients may benefit.